Trial · NCT03961659
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
NCT03961659, Not applicable, Unknown, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy. Trials, record NCT03961659. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03961659
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.
- NCT number
- NCT03961659
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 87 participants, estimated
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Cognitive Impairment
- Interventions
- Liraglutid, Dapagliflozin, Acarbose
- First posted
- 2019-05-23
- Last updated
- 2019-05-23
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of olfactory brain activation by fMRI | from baseline to 16 weeks' follow-up. | Compare the change of olfactory brain activation by fMRI from baseline to 16 weeks' follow-up |
| Secondary | Change of cognitive function | from baseline to 16 weeks' follow-up. | Compare the change of Montreal Cognitive Assessment (MoCA, beijing version) from baseline to 16 weeks' follow-up. MoCA score(ranging from 0 to 30)\<26 is considered cognitive impairment and when the score is lower, the cognitive impairment is more serious. MoCA score ≥26 is considered normal cognition. |
| Secondary | Proportion of patients whose MoCA<26 scores | at baseline and at 16 weeks' follow-up. | Compare the proportion of patients whose MoCA\<26 scores at baseline and at 16 weeks' follow-up. |
| Secondary | Change of blood glycaemic control | from baseline to 16 weeks' follow-up | Compare the change of glycosylated hemoglobin(HbA1c) from baseline to 16 weeks' follow-up |
| Secondary | Proportion of patients whose HbA1c<7% | at 16 weeks' follow-up. | Analyze the proportion of patients whose HbA1c\<7% at 16 weeks' follow-up. |
| Secondary | Proportion of patients whose weight loss>3% and >5% | from baseline to 16 weeks' follow-up. | Analyze the proportion of patients whose weight loss\>3% and \>5% |
| Secondary | Olfactory threshold test | from baseline to 16 weeks' follow-up. | The olfactory threshold test (score range 1-13.5) is determined based on a series of binary dilutions of the N-butanol solution in light mineral oil. The higher the score is, the more sensitive the participant is in detecting an odor. Scores of 8-10 were considered normal olfactory sensitivity, whereas scores of 1-3 signified olfactory dysfunction or anosmia, and scores of ≥10 indicate better olfactory sensitivity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35263425 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03961659
GET https://conductscience.org/api/trials/v1/NCT03961659/registered